ValiRx Share News (VAL)

ValiRx inks evaluation deal with Imperial College London for research

(Alliance News) - ValiRx PLC on Thursday said that it has signed an evaluation deal with Imperial College London to look at research on novel therapeutic candidates for cancer treatment.

EARNINGS AND TRADING: Ten Lifestyle sees profit up but sales flat

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

ValiRx says requisition notice from shareholder group is invalid

(Alliance News) - ValiRx PLC on Tuesday said a requisition notice, which it received earlier in February, has been confirmed as invalid following legal advice.

ValiRx inks deal with Dundee Drug Discovery Unit

(Sharecast News) - ValiRx announced the signing of a significant agreement with the University of Dundee and its Drug Discovery Unit (DDU) on Monday.

IN BRIEF: ValiRx signs research sharing deal with Dundee University

ValiRx PLC - Nuneaton, England-based life sciences company focused on early-stage cancer therapeutics - Signs agreement with Dundee University's drug discovery unit to access research concerning novel therapeutic candidates. The agreement will be active for a period of five years, in which ValiRx may review research projects from the unit in areas aligned with the company's focus on cancer therapeutics.

TRADING UPDATES: ValiRx receives shareholder request for board change

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

UK shareholder meetings calendar - next 7 days

IN BRIEF: ValiRx raises GBP192,200, part of wider GBP1.8 million raise

ValiRx PLC - life science company based near Birmingham, England, which is focused on early-stage cancer therapeutics and women's health - Says 3.2 million new shares have been subscribed for at 6 pence per share via a retail offer, raising GBP192,244. Also issues 499,998 new shares via a subscription. In total, raises GBP1.8 million via placing, subscription and retail offer of 30.0 million new shares.

TRADING UPDATES: Good Energy says ZapMap expands into mainland Europe

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

ValiRx enters option deal with Ambrose Healthcare

(Sharecast News) - Cancer therapeutics-focussed life science company ValiRx announced on Tuesday that its subsidiary ValiSeek has entered into an exclusive option agreement with Ambrose Healthcare, a private UK-based pharmaceutical company.

ValiRx says ValiSeek inks deal to licence VAL401 drug with Ambrose

(Alliance News) - ValiRx PLC on Tuesday said that ValiSeek Ltd it has entered a deal to licence VAL401 with Ambrose Healthcare Ltd, a private UK specialist pharmaceutical company.

AIM WINNERS & LOSERS: tinyBuild warns on revenue; ValiRx rises

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

ValiRx signs deal to evaluate StingRay Bio drug candidates

(Alliance News) - ValiRx PLC on Friday said it has signed a deal with StingRay Bio Ltd to investigate a series of drug candidates.

ValiRx enters partnership with StingRay Bio

(Sharecast News) - Life science company ValiRx announced a new partnership with StingRay Bio on Friday, aiming to explore a promising lead series of drug candidates designed for oncology applications.

ValiRx sees no reason for shares jump; notes TheoremRx mulls merger

(Alliance News) - ValiRx PLC on Friday said it had no unpublished information that was sensitive to its share price, as it rose significantly.